Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prophylactic Hyperthermic IntraperitOneal Chemotherapy (p-HIPEC) for pRevention of perItONeal Recurrence in Gastric Cancer: MC240402 (HORIZON) Trial

NCT07139951 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT07139951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07139951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prophylactic Hyperthermic IntraperitOneal Chemotherapy (p-HIPEC) for pRevention of perItONeal Recurrence in Gastric Cancer: MC240402 (HORIZON) Trial
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Enrolling by invitation
Start date
December 3, 2025
Completion date
November 3, 2031
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage i gastric cancer ajcc v8, clinical stage i gastroesophageal junction adenocarcinoma ajcc v8, clinical stage ii gastric cancer ajcc v8, clinical stage ii gastroesophageal junction adenocarcinoma ajcc v8, clinical stage iii gastric cancer ajcc v8, clinical stage iii gastroesophageal junction adenocarcinoma ajcc v8, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma